COVAXX, a US company developing a multitope synthetic peptide-based vaccine to fight COVID-19, has announced a global logistics partnership with Maersk, one of the world’s largest shipping and integrated logistics providers.
The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world, once approved by regulatory authorities. Financial terms of the agreement are not disclosed.
The mission of COVAXX is to defeat COVID-19 and ultimately democratize health worldwide. Maersk will help fulfill this mission by overseeing all logistics activities to ensure efficient transportation to developing countries.
The agreement provides for end-to-end supply chain management, packing and shipping, via air or ocean, ground transportation, warehouse storage and distribution to facilities to support COVAXX’s requirements for a pharmaceutical grade, temperature-controlled supply chain.
COVAXX is planning to manufacture 100 million doses of UB-612 during early 2021, and a billion doses by the end of 2021.
The design of the vaccine components will allow for the use of existing cold-chain storage and distribution channels, as the COVAXX vaccine does not require additional infrastructure such as -80⁰C freezers or liquid nitrogen tanks to store materials at extreme temperatures.